U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   FORM 10-QSB
(Mark One)

[X] QUARTERLY REPORT PURSUANT SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2001

[ ] TRANSITION REPORT PURSUANT SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

For the transition period from                 to
                                 --------------   -------------
Commission file number  0-27865

                            DISEASE SCIENCES, INC.
      (Exact name of small business issuer as specified in it charter)

              DELAWARE                              13-264091
              --------                              ---------
   (State of other jurisdiction of                  (IRS Employer
    incorporation or organization)                  Identification No.)

             20283 State Road 7 Suite 400 Boca Raton, FL 33498
             ------------------------------------------------------
                    (Address of principal executive offices)

                                 (561) 487-3655
                                 --------------
                           (Issuer's telephone number)


Indicate the number of shares outstanding of each of the Issuer's classes of
common stock, as of the latest practicable date: 87,439,002 shares of common
stock, $0.001 par value as of September 1, 2001.

Transitional Small Business Disclosure Format (check one);
Yes [ ]    No  [X]

<PAGE>

                             Disease Sciences, Inc.
                      (formerly "AuctionAnything.com, Inc.)

                                      INDEX


PART 1.  FINANCIAL INFORMATION                                          2

Item 1.  Financial Statements

         Condensed Consolidated Balance Sheet - July 31, 2001           3

         Condensed Consolidated Statements of Operations
          (unaudited) for the Three and Six Months Ended
          July 31, 2001 and 2000                                        4

         Condensed Consolidated Statement of Cash Flows
          (unaudited) for the Six Months Ended
          July 31, 2001 and 2000 and                                    5

         Notes to Financial Statements                                 6-7

                                       1
<PAGE>

Part I FINANCIAL INFORMATION

Item 1. Financial Statements

Basis of Financial Statements

The unaudited condensed  consolidated financial statements have been prepared in
conformity  with  generally  accepted  accounting  principles  and  include  all
adjustments  which are,  in the  opinion  of  management,  necessary  for a fair
presentation  of the  results  for  the  interim  periods  presented.  All  such
adjustments are, in the opinion of management, of a normal recurring nature.

The  results of  operations  for the three  months and six months  ended are not
necessarily indicative of those for the full year. In the opinion of management,
the  accompanying   unaudited  financial   statements  contain  all  adjustments
necessary to fairly present the financial position and the results of operations
for the periods indicated.

Certain  information  and footnote  disclosures  normally  included in condensed
consolidated financial statements prepared in accordance with generally accepted
accounting principles have been condensed or omitted. It is suggested that these
condensed  consolidated  financial  statements be read in  conjunction  with the
financial  statements and notes thereto  included in the Company's annual report
on Form 10-KSB for the year ended January 31, 2001.

                                        2
<PAGE>

                             DISEASE SCIENCES, INC.
                      (formerly "AuctionAnything.com, Inc.)
                        (A Development Stage Enterprise)
                                  JULY 31, 2001
                      CONDENSED CONSOLIDATED BALANCE SHEET
                                   (UNAUDITED)

                                     ASSETS
Current assets:
     Cash                                                  $       334,272
     Investments                                                     1,500
     Other current assets                                            4,008
                                                              -------------
                                                                   339,780

Equipment                                                            1,771
                                                              -------------
                                                           $       341,551
                                                              =============

                      LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
     Accounts payable and accrued expenses                 $        14,322
     Notes payable                                                 140,000
                                                             --------------
                                                                   154,322

Stockholders' equity:
     Common stock, $.001 par value; 100,000,000 authorized,
        92,080,966 issued                                           92,081
     Treasury stock, 8,021,964 shares at cost                     (106,500)
     Additional paid in capital                                    240,155
     Accumulated deficit                                           (38,507)
                                                              -------------
        Total stockholders' equity                                 187,229
                                                              -------------
                                                           $       341,551
                                                              =============



                        See notes to financial statements
                                        3

<PAGE>

                             DISEASE SCIENCES, INC.
                      (formerly "AuctionAnything.com, Inc.)
                        (A Development Stage Enterprise)
                 CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
               THREE AND SIXTH MONTHS ENDED JULY 31, 2001 AND 2000
                                   (UNAUDITED)


                                     Three Months Ended      Six Months Ended
                                          July 31,               July 31,
                                     2001         2000       2001        2000
                                  ---------   ----------  ---------   ---------
OPERATING EXPENSES              $   37,606    $    -      $ 38,507   $   -
                                  ---------   ----------  ---------   ---------
NET LOSS                        $  (37,606)   $    -      $(38,507)  $   -
                                  =========   ==========  =========   =========
NET LOSS PER WEIGHTED AVERAGE
 SHARES OUTSTANDING
 BASIC AND DILUTED              $    (-)      $    -      $  (-)     $   -
                                  =========   ==========  =========   =========
WEIGHTED AVERAGE COMMON SHARES
 OUTSTANDING                      69,042,872  28,321,946  48,916,784  26,732,000
                                  ==========  ==========  ==========  ==========



                        See notes to financial statements
                                        4

<PAGE>

                             DISEASE SCIENCES, INC.
                      (formerly "AuctionAnything.com, Inc.)
                        (A Development Stage Enterprise)
                  CONDENSED CONSOLIDTAD STATEMENT OF CASH FLOWS
                    SIXTH MONTHS ENDED JULY 31, 2001 AND 2000
                                   (UNAUDITED)


                                                      2001             2000
                                                --------------    ------------
NET LOSS                                      $       (38,507)   $       -
                                                --------------    ------------
Adjustments to reconcile net loss to net
  cash provided by operating activities:
Changes in assets and liabilites:
    Increase in other assets                           (4,008)           -
    Increase in accounts payable                       14,322            -
                                                --------------    ------------
NET CASH USED IN OPERATIONS                           (28,193)           -
                                                --------------    -------------
CASH FLOWS FROM INVESTING ACTIVITIES
    Purchase of investment                             (1,500)           -
    Purchase of equipment                              (1,771)           -
                                                --------------    -------------
NET CASH USED IN INVESTING ACTIVITIES                  (3,271)           -
                                                --------------    -------------
CASH FLOWS FROM FINANCING ACTIVITIES
    Notes payable                                     140,000            -
    Repurchase of treasury stock                     (106,500)           -
    Sale of common stock                              332,236            -

NET CASH PROVIDED BY
    FINANCING ACTIVITIES                              365,736            -
                                                --------------     ------------
NET INCREASE IN CASH                                  334,272            -
                                                --------------     ------------
CASH, beginning of period                                -               -
                                                --------------     ------------
CASH, end of period                           $       334,272 $          -
                                                ==============    =============


                        See notes to financial statements
                                        5

<PAGE>

                             Disease Science, Inc.
                      (formerly "AuctionAnything.com, Inc.)
              Notes to Condensed Consolidated Financials Statements
                                    unaudited

Summary of Significant Accounting Policies

1. ORGANIZATION

Disease   Sciences,   Inc.  (the  "Company"),   A  Delaware   corporation  is  a
developmental  stage   biopharmaceutical/clinical   diagnostics   company.   The
Company's  long-term  goal is to become a  partially  integrated  pharmaceutical
company with capabilities in research, drug development, clinical investigation,
and  regulatory  affairs.  The  Company is  planning  to employ a broad array of
technologies  to detect,  identify  and  quantify  substances  in blood or other
bodily fluids and tissues. The company intends to target and develop proprietary
pharmaceutical  compounds  and new  technologies.  Its  primary  goal will be to
develop a Transmissible  Spongiform  Encephalopathy  ("TSE") test, useful in the
diagnosis  of  TSE  diseases  such  as  scrapie  in  sheep,   Bovine  Spongiform
Encephalopathy  (BSE) in cattle (commonly known as "mad-cow  disease"),  Chronic
Wasting Disease (CWD) in wild deer and elk and  Creutzfeldt-Jakob  Disease (CJD)
in humans. The Company believes these test results may be used in the diagnosis,
detection, evaluation,  monitoring and potential treatment of diseases and other
medical conditions.


On May 23, 2001, the Company completed the acquisition of 100% of the issued and
outstanding  common  stock of Disease  S.I.,  Inc., a Florida  corpotation.  The
Company  acquired  100% of the issued and  outstanding  stock of Disease S.I. in
exchange for 60,000,000 shares of Common Stock.

The acquisition of Disease SI by has been accounted for as a reverse acquisition
under the purchase method for business combinations.  The combination of the two
companies  is recorded as a  recapitalization  of Disease SI,  pursuant to which
Disease is treated as the continuing entity.

Effective July 24, 2001, the Company completed the sale of, North Orlando Sports
Promotions,  a wholly owned  subsidiary  of the Company all  operating  lines of
business its former  management  group.  Until the sale it was a BusinesInternet
Business Solutions ("IBS"): a service which establishes and hosts auction and/or
E-commerce web sites for other  businesses and  organizations  primarily in both
the business-to-business and business-to-consumer markets.

2. NOTES PAYABLE

On May 23, 2001 the Company  borrowed a total of $140,000 from two  unaffiliated
third parties. The notes are unsecured, payable upon demand and bear interest at
9% per annum.

3. TREASRY STOCK

In May 2001, the Company,  repurchased  an aggregate of 8,021,694  shares of its
common stock owned from a former director of the Company, and a company which he
controls,  for an aggregate  purchase price of $106,500.  These shares have been
cancelled  and  returned  to the  treasury  of the  Company  with the  status of
authorized but unissued shares.

                                       6

<PAGE>

4. Private Placement

The Company  completed a private  placement  of  4,700,000  Units (the Units) in
August of 2001.  As Of July 31 2001 the  Company  had sold a total of  3,290,000
units.  Each Unit  consists of one share of Common  Stock,  $.001 par value (the
Common  Stock) and four common  stock  purchase  warrants  designated  Series A,
Series B, Series C and Series D common stock purchase warrants (collectively the
Warrants).  The Series A Warrant  included in each Unit  entitles  the holder to
purchase  one share of Common  Stock of the Company at a purchase  price of $.30
per share.  The Series B Warrant  included in each Unit  entitles  the holder to
purchase  one share of Common  Stock of the Company at a purchase  price of $.60
per share.  The Series C Warrant  included in each Unit  entitles  the holder to
purchase One share of Common  Stock of the Company at a purchase  price of $1.00
per share.  The Series D Warrant  included in each Unit  entitles  the holder to
purchase one share of common Stock of the Company at the Purchase Price of $2.00
per share.  The  Warrants  will expire on May 1, 2006.  The Company may call any
Warrant  series or all of the  Warrants at a call price of $.001 per  underlying
share should the Company's Common Stock trade at or above $5.00 per share, based
on the  reported  closing  bid price of the Common  Stock,  for ten  consecutive
trading days following 15 days prior written  notice of the Company's  intention
to call the  Warrants.  In the event the Warrants or Warrant  series  subject to
call have not been exercised by written notice within such 15-day notice period,
the Warrants will cease to exist.

 5. Recent Accounting Pronouncements

In July 2001, FASB issued SFAS No. 141,  "Business  Combinations."  SFAS No. 141
requires the purchase method of accounting for business  combinations  initiated
after June 30, 2001 and eliminates the  pooling-of-interests  method. We believe
that the  adoption  of SFAS No.  141 will not have a  significant  impact on our
financial statements.

In July 2001, FASB issued SFAS No. 142, "Goodwill and Other Intangible  Assets",
which is effective for fiscal years  beginning after December 15, 2001. SFAS No.
142 requires,  among other things, the discontinuance of goodwill  amortization.
In  addition,   the  standard   includes   provisions   upon  adoption  for  the
reclassification  of  certain  existing  recognized   intangibles  as  goodwill,
reassessment   of  the  useful   lives  of  existing   recognized   intangibles,
reclassification  of certain intangibles out of previously reported goodwill and
the testing for impairment of existing  goodwill and other  intangibles.  We are
currently  assessing but have not yet  determined  the impact of SFAS No. 142 on
our financial position and results of operations.

6. Subsequent Events

In August 2001 two Directors of the Company  exercised stock options  previously
granted to them under the Company's stock option Plan to each acquire  1,000,000
shares of our common stock. As consideration for the exercise price of $.155 per
share,  each  of the  Directors  issued  to the  Company  a one  year  unsecured
promissory note in the principal  amount of $155,000,  bearing  interest at 5.5%
per annum.



                                        7
<PAGE>


Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

         The following discussion should be read together with the information
contained in the financial statements and related notes included elsewhere in
this report.

Plan of operation

         From 1999 until July 2001, we operated a variety of  Internet - related
services.  We were,  however,  unable to generate  positive cash flow from these
Internet-related businesses. On May 23, 2001, we acquired 100% of the issued and
outstanding  stock of Disease SI,  Inc.  ("Disease  SI"),  a  development  stage
biopharmaceutical/clinical  diagnostics  company,  in  exchange  for  60,000,000
shares of our common stock.  Following  completion of the acquisition of Disease
SI, it  became  apparent  to us that it would be in our best long term  interest
that    the    Internet    operations    be    conducted    apart    from    our
biopharmaceutical/clinical  diagnostics operations.  On July 24, 2001, we sold a
former  director all of the capital  stock of North Orlando  Sports  Promotions,
Inc.,  our  wholly-owned  subsidiary,  in  exchange  for the  assumption  of all
liabilities   related  to  North  Orlando  and  its   operations   estimated  at
approximately $112,000, and which included the forgiveness of $91,500 in accrued
compensation. Included in the sale along with the capital stock of North Orlando
were fixed assets, rights to several domain names and various contractual rights
and obligations.

          Following the sale of North Orlando, our long-term goal is to become a
partially integrated  pharmaceutical company with capabilities in research, drug
development,  clinical  investigation,  and regulatory affairs.  Since May 2001,
working  capital to fund our  operations  was  generated  from the  proceeds  of
approximately  $470,000  received  by us  from  the  private  placement  of  our
securities.  During the  balance of fiscal 2001 our plan of  operation  includes
further  research and  development of a TSE screening test, and the extension of
its  technologies  to  several  other  forms of TSE.  We are  planning  clinical
studies,  the costs of which will be borne by us. In furtherance of thereof,  in
August 2001 we agreed to fund a research grant of  approximately  $280,000 for a
two year study on the efficacy of incineration to inactive scrapie prions. Other
than this initial  study,  at this time we are unable to project the total costs
of these clinical studies due to the early stage of our focus in this area.

         We do not expect operating revenue in the foreseeable future. We expect
to generate losses resulting principally from costs incurred in conjunction with
our research and development initiatives,  including costs related to scientific
and laboratory personnel, clinical studies and reagents and supplies used in the
development of our technologies, and we expect that the cost of our research and
development  activities will increase substantially as the implementation of our
business plan  continues.  In addition,  as we continue to implement our plan of
operation,   we  expects  general  and   administrative   expenses  to  increase
significantly as we hires additional  personnel and builds our infrastructure to
support future projected growth.  These general and administrative  expenses are
expected  to  consist  primarily  of  non-research  personnel  salaries,  office
expenses and professional  fees. We are unable at this time to project the total
costs of these additional general and administrative expenses.

                                      8

<PAGE>

         In order to provide sufficient  working  capital  to  fund our  ongoing
operations  we will be  required  to  raise  additional  capital  to fund  these
anticipated  costs.  There are no assurances  that we will be able to obtain the
additional  capital in which event our future operations would be materially and
adversely affected.

Liquidity and Capital Resources

         Our working capital at  July 31, 2001  was  $185,458,  and increase  of
$209,757 from January 31, 2001. This increase is  attributable to  approximately
$470,000 in working capital raised in August 2001 in a private  placement of our
securities.  Other than our existing working  capital,  we do not have any other
internal sources of working capital.

         Since inception, our operating and investing activities have used  more
cash than they have  generated.  Because of the continued  need for  substantial
amounts of  working  capital  to fund the  growth of the  business,  to meet our
commitment for research funding and to pay our operating expenses, we expects to
continue to experience  significant  negative operating and investing cash flows
for the foreseeable  future. Our existing working capital will not be sufficient
to fund the continued implementation of our plan of operation during the next 12
months and to meet our capital  commitments and general operating  expenses.  We
are  unable  to  predict  at this time the exact  amount of  additional  working
capital we will require,  however,  in order to provide any  additional  working
capital  which we may require,  we will in all  likelihood  be required to raise
additional  capital through the sale of equity or debt securities.  We currently
have no commitments to provide us with any additional working capital.  If we do
not have sufficient working capital to implement our plan of operation described
above, it is likely that we will cease operations.


                                       9


<PAGE>

Part II - OTHER INFORMATION

Item 1.  Legal Proceedings

Not applicable

Item 2.  Changes in Securities

Not applicable

Item 3.  Defaults upon Senior Securities

Not applicable

Item 4.  Submission of Matters to a Vote of Security Holders

Not applicable

Item 5.  Other Information

Not applicable


Item 6.  Exhibits and Reports on Form 8-K

(a) Exhibits

The following  documents are filed herewith or have been included as exhibits to
previous  filings  with  the  Commission  and are  incorporated  herein  by this
reference:

         None


(b) Reports on Form 8-K

Form  8-K  was  filed  on  June  29,  2001  pertaining  to  the  acquisition  of
AuctionAnything.com, Inc.



                                       10
<PAGE>

SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

AUCTIONANYTHING.COM, INC.



by /s/Dr. Wayne Goldstein
-----------------------------
Dr. Wayne Goldstein, President and CEO



Date: September 21, 2001







                                       11